These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28750808)

  • 21. Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy.
    Garai S; Leo LM; Szczesniak AM; Hurst DP; Schaffer PC; Zagzoog A; Black T; Deschamps JR; Miess E; Schulz S; Janero DR; Straiker A; Pertwee RG; Abood ME; Kelly MEM; Reggio PH; Laprairie RB; Thakur GA
    J Med Chem; 2021 Jun; 64(12):8104-8126. PubMed ID: 33826336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological Evaluation of Cannabinoid Receptor Modulators Using GRAB
    Shivshankar S; Nimely J; Puhl H; Iyer MR
    Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Silico Prediction and Validation of CB2 Allosteric Binding Sites to Aid the Design of Allosteric Modulators.
    Yuan J; Jiang C; Wang J; Chen CJ; Hao Y; Zhao G; Feng Z; Xie XQ
    Molecules; 2022 Jan; 27(2):. PubMed ID: 35056767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allosteric Modulators of the CB
    Morales P; Goya P; Jagerovic N; Hernandez-Folgado L
    Cannabis Cannabinoid Res; 2016; 1(1):22-30. PubMed ID: 28861476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery.
    Gado F; Meini S; Bertini S; Digiacomo M; Macchia M; Manera C
    Future Med Chem; 2019 Aug; 11(15):2019-2037. PubMed ID: 31517528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aiming for allosterism: Evaluation of allosteric modulators of CB1 in a neuronal model.
    Straiker A; Mitjavila J; Yin D; Gibson A; Mackie K
    Pharmacol Res; 2015 Sep; 99():370-6. PubMed ID: 26211948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In silico mapping of allosteric ligand binding sites in type-1 cannabinoid receptor.
    Sabatucci A; Tortolani D; Dainese E; Maccarrone M
    Biotechnol Appl Biochem; 2018 Jan; 65(1):21-28. PubMed ID: 28833445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enantiomer-specific positive allosteric modulation of CB
    Mitjavila J; Yin D; Kulkarni PM; Zanato C; Thakur GA; Ross R; Greig I; Mackie K; Straiker A
    Pharmacol Res; 2018 Mar; 129():475-481. PubMed ID: 29158048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allosteric properties of G protein-coupled receptor oligomers.
    Springael JY; Urizar E; Costagliola S; Vassart G; Parmentier M
    Pharmacol Ther; 2007 Sep; 115(3):410-8. PubMed ID: 17655934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Divalent cannabinoid-1 receptor ligands: A linker attachment point survey of SR141716A for development of high-affinity CB1R molecular probes.
    Grant PS; Kahlcke N; Govindpani K; Hunter M; MacDonald C; Brimble MA; Glass M; Furkert DP
    Bioorg Med Chem Lett; 2019 Nov; 29(21):126644. PubMed ID: 31564385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Positive Allosteric Modulation of CB1 and CB2 Cannabinoid Receptors Enhances the Neuroprotective Activity of a Dual CB1R/CB2R Orthosteric Agonist.
    Polini B; Cervetto C; Carpi S; Pelassa S; Gado F; Ferrisi R; Bertini S; Nieri P; Marcoli M; Manera C
    Life (Basel); 2020 Dec; 10(12):. PubMed ID: 33302569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects.
    Ignatowska-Jankowska BM; Baillie GL; Kinsey S; Crowe M; Ghosh S; Owens RA; Damaj IM; Poklis J; Wiley JL; Zanda M; Zanato C; Greig IR; Lichtman AH; Ross RA
    Neuropsychopharmacology; 2015 Dec; 40(13):2948-59. PubMed ID: 26052038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity.
    Dopart R; Lu D; Lichtman AH; Kendall DA
    Drug Metab Rev; 2018 Feb; 50(1):3-13. PubMed ID: 29355030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CB1 receptor binding sites for NAM and PAM: A first approach for studying, new n‑butyl‑diphenylcarboxamides as allosteric modulators.
    Gado F; Ceni C; Ferrisi R; Sbrana G; Stevenson LA; Macchia M; Pertwee RG; Bertini S; Manera C; Ortore G
    Eur J Pharm Sci; 2022 Feb; 169():106088. PubMed ID: 34863873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual modulation of CNS voltage-gated calcium channels by cannabinoids: Focus on CB1 receptor-independent effects.
    Lozovaya N; Min R; Tsintsadze V; Burnashev N
    Cell Calcium; 2009 Sep; 46(3):154-62. PubMed ID: 19682741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opportunities and Challenges in the Discovery of Allosteric Modulators of GPCRs.
    Bartuzi D; Kaczor AA; Matosiuk D
    Methods Mol Biol; 2018; 1705():297-319. PubMed ID: 29188568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allosteric modulation of adenosine A1 and cannabinoid 1 receptor signaling by G-peptides.
    Touma AM; Malik RU; Gupte T; Sivaramakrishnan S
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00673. PubMed ID: 33124765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Focused structure-activity relationship profiling around the 2-phenylindole scaffold of a cannabinoid type-1 receptor agonist-positive allosteric modulator: site-III aromatic-ring congeners with enhanced activity and solubility.
    Schaffer PC; Kulkarni PM; Janero DR; Thakur GA
    Bioorg Med Chem; 2020 Nov; 28(21):115727. PubMed ID: 33065437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allosteric modulation of G protein-coupled receptors: a pharmacological perspective.
    Keov P; Sexton PM; Christopoulos A
    Neuropharmacology; 2011 Jan; 60(1):24-35. PubMed ID: 20637785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias.
    Manning JJ; Green HM; Glass M; Finlay DB
    Neuropharmacology; 2021 Aug; 193():108611. PubMed ID: 34000272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.